{"filing":{"accession_number":"0001140361-26-040631","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"ef20084325_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126040631/ef20084325_8k.htm"},"events":[{"id":37536,"run_id":34594,"accession_number":"0001140361-26-040631","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Ionis disclosed positive Phase 3 clinical trial data for sefaxersen, a partnered investigational drug licensed to Roche, showing a statistically significant 43.1% reduction in proteinuria in IgA nephropathy patients with a consistent safety profile. This material clinical milestone affects investor assessment of the drug's commercial potential and Ionis' future royalty and milestone payments from the partnership.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42276,"accession_number":"0001140361-26-040631","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis disclosed positive Phase 3 clinical trial data for sefaxersen, a partnered investigational drug, showing statistically significant 43.1% reduction in proteinuria in IgA nephropathy patients. This represents a material operational/clinical milestone for a key pipeline asset under development with Roche, affecting investor assessment of the company's therapeutic prospects and potential future revenue streams from milestone and royalty payments. While not a traditional earnings release or M\u0026A event, the positive clinical data is material to the registrant's business prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T17:42:41.151796+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42277,"accession_number":"0001140361-26-040631","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces positive Phase 3 clinical trial results for sefaxersen, an investigational drug licensed to Roche by Ionis. The announcement of a 43.1% reduction in proteinuria with statistical significance (P\u003c0.0001) and consistent safety profile represents a material clinical milestone that could affect investor assessment of the drug's commercial potential and Ionis' future royalty and milestone payments. While this is a clinical development milestone rather than a traditional operational event, it is clearly material to the registrant's business prospects and does not fit neatly into other categories (not earnings, not M\u0026A, not litigation, not a restatement or going-concern issue).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T17:42:41.151796+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42276,"accession_number":"0001140361-26-040631","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis disclosed positive Phase 3 clinical trial data for sefaxersen, a partnered investigational drug, showing statistically significant 43.1% reduction in proteinuria in IgA nephropathy patients. This represents a material operational/clinical milestone for a key pipeline asset under development with Roche, affecting investor assessment of the company's therapeutic prospects and potential future revenue streams from milestone and royalty payments. While not a traditional earnings release or M\u0026A event, the positive clinical data is material to the registrant's business prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T17:42:41.151796+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-10-23"},{"id":42277,"accession_number":"0001140361-26-040631","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces positive Phase 3 clinical trial results for sefaxersen, an investigational drug licensed to Roche by Ionis. The announcement of a 43.1% reduction in proteinuria with statistical significance (P\u003c0.0001) and consistent safety profile represents a material clinical milestone that could affect investor assessment of the drug's commercial potential and Ionis' future royalty and milestone payments. While this is a clinical development milestone rather than a traditional operational event, it is clearly material to the registrant's business prospects and does not fit neatly into other categories (not earnings, not M\u0026A, not litigation, not a restatement or going-concern issue).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T17:42:41.151796+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-10-23"}]}